GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Momentum Rank

Regnum (Regnum) Momentum Rank : 0 (As of Apr. 30, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Regnum Momentum Rank?

Regnum has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Regnum Momentum Rank Related Terms

Thank you for viewing the detailed overview of Regnum's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Regnum (Regnum) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Momentum Rank
Comparable Companies
QBIO CALA PPCB RGIN RSPI RGTPQ ATRX HGEN MYMX NMTRQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
600 Third Avenue, 19th Floor, New York, NY, USA, 10016
Website
https://www.regnumcorp.com
Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines